The startup develops genome analysis technology that enables contract testing and analysis services to detect minute quantities of bacteria in embryos by examining their genes and chromosomes. This technology helps identify genetic abnormalities before pregnancy, thereby alleviating physical and mental burdens for women.
Funding
$10.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FTIFounders
Product
Problem
Infertility affects a significant number of couples, with many cases remaining unexplained even after thorough examination of both partners. Traditional methods of assessing fertility potential often overlook the critical role of the uterine environment and the genetic health of embryos. This can lead to repeated unsuccessful attempts at conception and increased emotional and financial burden for individuals seeking to start a family.
Solution
Varinos is a clinical testing company that utilizes advanced genomic analysis to improve the success rates of assisted reproductive technologies. The company's core offering includes the Uterine Microbiome Test, which analyzes the uterine flora to identify microbial imbalances that may hinder embryo implantation. Varinos also provides Preimplantation Genetic Testing for Aneuploidy (PGT-A), which screens embryos for chromosomal abnormalities before in vitro fertilization (IVF), helping to select the most viable embryos for transfer. By combining insights into the uterine environment with embryo screening, Varinos aims to provide a comprehensive assessment of fertility potential, ultimately increasing the likelihood of successful pregnancies and healthy births.
Target Audience
Varinos serves individuals and couples undergoing fertility treatment, as well as reproductive endocrinologists, IVF clinics, and other healthcare providers specializing in reproductive medicine.
Features
- Uterine Microbiome Test: Employs next-generation sequencing (NGS) to identify and quantify the types and proportions of bacteria present in the uterine cavity.
- PGT-A: Utilizes comprehensive chromosome screening (CCS) to detect aneuploidies (abnormal chromosome numbers) in preimplantation embryos.
- Proprietary algorithms for data analysis and reporting, providing clinicians with actionable insights.
- ISO/IEC 27001 certification and CAP-LAP accreditation, ensuring data security and quality control.
- Counseling services to help patients understand test results and make informed decisions about their fertility treatment options.
- Research and development efforts focused on expanding the application of genomics in reproductive medicine.